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http://dx.doiabstractBACKGROUND: Tuberous sclerosis complex is highly variable in clinical presentation and ﬁndings. Disease mani-
festations continue to develop over the lifetime of an affected individual. Accurate diagnosis is fundamental to
implementation of appropriate medical surveillance and treatment. Although signiﬁcant advances have been
made in the past 15 years in the understanding and treatment of tuberous sclerosis complex, current clinical
diagnostic criteria have not been critically evaluated or updated since the last clinical consensus conference
in 1998.METHODS: The 2012 International Tuberous Sclerosis Complex Consensus Group, comprising 79 specialists
from 14 countries, was organized into 12 subcommittees, each led by a clinician with advanced expertise in tu-
berous sclerosis complex and the relevant medical subspecialty. Each subcommittee focused on a speciﬁc disease
area with important diagnostic implications and was charged with reviewing prevalence and speciﬁcity of disease-
associated clinical ﬁndings and their impact on suspecting and conﬁrming the diagnosis of tuberous sclerosis
complex. RESULTS: Clinical features of tuberous sclerosis complex continue to be a principal means of diagnosis. Key
changes compared with 1998 criteria are the new inclusion of genetic testing results and reducing diagnostic
classes from three (possible, probable, and deﬁnite) to two (possible, deﬁnite). Additional minor changes to speciﬁc
criterion were made for additional clariﬁcation and simpliﬁcation. CONCLUSIONS: The 2012 International Tuberous
Sclerosis Complex Diagnostic Criteria provide current, updated means using best available evidence to establish
diagnosis of tuberous sclerosis complex in affected individuals.
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 2013 Elsevier Inc.Open access under CC BY-NC-ND license. See related articles on pages 223 and 255.Introduction
Tuberous sclerosis complex (TSC) was initially described
approximately 150 years ago by von Recklinghausen in
1862.1 TSC is an extremely variable disease that can affect
virtually any organ in the body. The most common ﬁndings
are benign tumors in the skin, brain, kidneys, lung, and
heart that lead to organ dysfunction as the normalory:
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Open access under CC BY-NC-ND license. parenchyma is replaced by a variety of cell types.2 Disease
manifestations in different organ systems can vary widely
between even closely related individuals and the protean
nature of the condition can make clinical diagnosis chal-
lenging. TSC was underdiagnosed until the 1980s when
individuals with less severe manifestations of the disease
began to be recognized. Before the 1980s, incidence rates
for TSC were quoted at between 1/100,000 and 1/
200,000.3,4 Recent studies estimate a frequency of 1/6000
to 1/10,000 live births and a population prevalence of
around 1 in 20,000.5,6 Although TSC was recognized to be a
genetic disease more than 100 years ago,7 the underlying
molecular etiology was not unraveled until the discovery of
the two causative genes, TSC1 and TSC2.8,9
The second International Tuberous Sclerosis Complex
Consensus Conference was held June 13-14, 2012, in
Washington, DC. Seventy-nine experts (Appendix) from 14
TABLE.
Updated diagnostic criteria for tuberous sclerosis complex 2012
A. Genetic diagnostic criteria
The identiﬁcation of either a TSC1 or TSC2 pathogenic mutation in DNA from normal tissue is sufﬁcient to make a deﬁnite diagnosis of tuberous
sclerosis complex (TSC). A pathogenic mutation is deﬁned as a mutation that clearly inactivates the function of the TSC1 or TSC2 proteins (e.g.,
out-of-frame indel or nonsense mutation), prevents protein synthesis (e.g., large genomic deletion), or is a missense mutation whose effect on
protein function has been established by functional assessment (www.lovd.nl/TSC1, www.lovd/TSC2, and Hoogeveen-Westerveld et al., 2012
and 2013). Other TSC1 or TSC2 variants whose effect on function is less certain do not meet these criteria, and are not sufﬁcient to make a
deﬁnite diagnosis of TSC. Note that 10% to 25% of TSC patients have no mutation identiﬁed by conventional genetic testing, and a normal result
does not exclude TSC, or have any effect on the use of clinical diagnostic criteria to diagnose TSC.
B. Clinical diagnostic criteria
Major features
1. Hypomelanotic macules (3, at least 5-mm diameter)
2. Angioﬁbromas (3) or ﬁbrous cephalic plaque
3. Ungual ﬁbromas (2)
4. Shagreen patch
5. Multiple retinal hamartomas
6. Cortical dysplasias*
7. Subependymal nodules





1. “Confetti” skin lesions
2. Dental enamel pits (>3)
3. Intraoral ﬁbromas (2)
4. Retinal achromic patch
5. Multiple renal cysts
6. Nonrenal hamartomas
Deﬁnite diagnosis: Two major features or one major feature with 2 minor features
Possible diagnosis: Either one major feature or 2 minor features
* Includes tubers and cerebral white matter radial migration lines.
y A combination of the two major clinical features (LAM and angiomyolipomas) without other features does not meet criteria for a deﬁnite diagnosis.
H. Northrup, D.A. Krueger / Pediatric Neurology 49 (2013) 243e254244countries convened to ﬁnalize diagnostic, surveillance, and
management recommendations for patients with TSC. A
summary report of the current, updated surveillance and
management recommendations for the standardized,
optimal clinical management of patients with TSC is pro-
vided separately.10 One of the major goals of the conference
was to revisit the clinical diagnostic criteria published
subsequent to the ﬁrst International TSC Consensus Con-
ference in 1998.11 Since 1998, one additional manuscript
regarding the diagnostic criteria has been published that
was designed to provide more guidance to practitioners by
including pictures of the major and minor ﬁndings.12 At the
2012meeting, themost signiﬁcant change recommended to
the diagnostic criteria was the incorporation of genetic
testing. Although the TSC1 and TSC2 genes were discovered
before the 1998 conference, molecular testing was not
widely available at that time. Molecular testing of the TSC1
and TSC2 genes yields a positive mutation result for 75-90%
of TSC-affected individuals categorized as “deﬁnite” by the
1998 Consensus Conference Clinical Diagnostic Criteria.2
The use of molecular testing in medicine has expanded
greatly since the 1990s, becoming widely accepted as
invaluable in the diagnosis of diseases with a genetic basis.
Utilization of genetic testing for TSC was addressed along
with reﬁnement of clinical criteria.Genetic diagnostic criteria
Comprehensive and reliable screens for TSC1 and TSC2
mutations are well-established, and many pathogenic mu-
tations have been identiﬁed (www.lovd.nl/TSC1, www.lovd/TSC2). The recommendation of the Genetics Panel was to
make identiﬁcation of a pathogenic mutation in TSC1 or
TSC2 an independent diagnostic criterion, sufﬁcient for the
diagnosis or prediction of TSC regardless of the clinical
ﬁndings (Table part A). This will facilitate the diagnosis of
TSC in some, particularly young individuals, allowing earlier
implementation of surveillance and treatment with poten-
tial for better clinical outcomes. A “pathogenic” mutation
was deﬁned as a mutation that clearly prevents protein
synthesis and/or inactivates the function of the TSC1 or
TSC2 proteins (e.g., nonsense mutation or frameshift mu-
tations, large genomic deletions) or is a missense mutation
whose effect on protein function has been established by
functional assessment.13,14 TSC1 and TSC2 genetic variants
whose functional effect is less certain are not deﬁnitely
pathogenic and would not be considered a major diagnostic
criterion. A signiﬁcant fraction (10-25%) of TSC patients
have no mutation identiﬁed by conventional genetic
testing. Therefore, a normal result does not exclude TSC.
Nonetheless, if the mutation in an affected relative is
known, testing for that mutation has very high predictive
value for family members. Assembled experts at the
Consensus Conference agreed with the recommendation
that identiﬁcation of a pathogenic mutation in TSC1 or TSC2
is an independent diagnostic criterion.Clinical diagnostic criteria
In addition to diagnosis by genetic analysis, the clinical
diagnostic criteria used to establish the diagnosis of TSC
were also reviewed at the conference. Special attentionwas
FIGURE 1.
Three hypopigmented macules the lower back/upper buttocks.
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ﬁndings with respect toTSC diagnosis. Panels were assigned
to the following focus areas for this process, and speciﬁc
attempts were made to reﬁne and simplify the clinical
diagnostic criteria that included 11 major features and nine
minor features according to the 1998 Conference. The in-
dividual panels were organized as follows: (1) dermatology
and dentistry; (2) ophthalmology; (3) brain structure, tu-
bers, and tumors; (4) epilepsy; (5) TSC-associated neuro-
psychiatric disorders; (6) cardiology; (7) pulmonology; (8)
nephrology; (9) endocrinology; (10) gastroenterology; and
(11) care integration. The recommendations of each panel
were presented to the entire congress for discussion,
modiﬁcation if necessary, and ﬁnal approval. The new,
updated diagnostic clinical criteria now include 11 major
features and six minor features (Table part B).
Dermatologic and dental features
The dermatology and dental panel recommended
retaining the existing mucocutaneous criteria and sug-
gested minor changes regarding their number, size, or
nomenclature. The major features (with changes italicized)
include: (1) hypomelanotic macules (3, at least 5-mm
diameter), (2) angioﬁbromas (3) or ﬁbrous cephalic pla-
que, (3) ungual ﬁbromas (2), and (4) shagreen patch. The
revised minor features include: (1) “confetti” skin lesions,FIGURE 2.
Facial angioﬁbromas.(2) dental enamel pits (3), and (3) intraoral ﬁbromas (2).
Nearly 100% of individuals affected with TSC have skin or
dental ﬁndings of the disease that are easily detectable on
physical examination. It is therefore important that these
features be highlighted to aid in bringing TSC patients to
medical attention.Hypomelanotic macules
Hypomelanotic macules are a signiﬁcant feature
because they are observed in about 90% of individuals with
TSC, they typically appear at birth or infancy, and they may
be a presenting sign of TSC (Fig 1).15-21 At the 1998
Consensus, it was stipulated that an individual must have
three or more hypopigmented macules, because one or
two lesions are relatively common in the general popula-
tion.22,23 In the updated criteria, it was recommended that
hypomelanotic macules meet a size requirement of at least
5-mm diameter to distinguish hypomelanotic macules
from smaller and more numerous “confetti” lesions. In
addition, it was suggested that poliosis, circumscribed
areas of hypomelanosis of hair, be included in the count of
hypomelanotic macules.Angioﬁbromas or ﬁbrous cephalic plaque
Facial angioﬁbromas occur in about 75% of TSC patients
(Fig 2),15,16,18,21 with onset typically between ages 2 and 5
years.24 Although most TSC patients have several facial
angioﬁbromas, milder cases of TSC with limited facial
angioﬁbromas have been described. However, because one
or two isolated sporadic lesions may be observed in the
general population,25 the presence of at least three facial
angioﬁbroma lesions is now recommended to meet this
major criteria for TSC. Multiple facial angioﬁbromas have
also been observed in Birt-Hogg-Dubé (BHD) syndrome,
and multiple endocrine neoplasia type 1 (MEN1).26,27 In
these conditions, the age of onset of angioﬁbromas is later
than in TSC. Therefore, multiple facial angioﬁbromas re-
mains a major feature for diagnosis when their onset occurs
in childhood. In the unusual circumstance when angioﬁ-
bromas have their onset in adulthood, they should be
considered as a minor feature and the differential diagnosis
expanded to include BHD and MEN1. When angioﬁbromas
are few or later in onset, a skin biopsy may be required to
conﬁrm the clinical diagnosis.
The forehead plaque is observed in about 25% of TSC
patients and this feature was paired with angioﬁbromas for
the diagnostic criteria in 1998 (Fig 3A). The panel recom-
mended changing the terminology from forehead plaque to
ﬁbrous cephalic plaque. This term was created to increase
awareness that these ﬁbrous plaques, although often
located unilaterally on the forehead, may occur on other
parts of the face or scalp (Fig 3B). Fibrous cephalic plaques,
which are histologically similar to angioﬁbromas, may be
the most speciﬁc skin ﬁnding for TSC.Ungual ﬁbromas
Ungual ﬁbromas were retained as a major feature (Fig 4).
The previous designation as “nontraumatic”was eliminated
because recall of traumamay be unreliable and traumamay
play a role in the formation of TSC ungual ﬁbromas.28 This




Shagreen patch on dorsolumbar area of back.
FIGURE 3.
(A) Fibrous plaque on face. (B) Fibrous plaque on scalp.
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general population in response to trauma are usually soli-
tary.29 The redundant phrase “ungual and periungual ﬁ-
bromas” was replaced with “ungual ﬁbromas” used to
encompass both periungual and subungual ﬁbromas. Un-
gual ﬁbromas are less common than some of the other TSC
skin ﬁndings, with a frequency of about 20% overall but as
high as 80% in older adults.15,16,28 The greater frequency in
adults is due to later onset, typically in the second decade or
later.18,21 Therefore, their utility in diagnosis is usually
limited to adolescents and adults.24Shagreen patch
The presence of a shagreen patch was retained as a major
feature, but the criterion was updated by deletion of “con-
nective tissue nevus” because this term encompasses a va-
riety of skin lesions with excessive dermal connective tissue
that are not necessarily associated with TSC. Shagreen
patches commonly take the form of large plaques on the
lower back that have a bumpy or orange-peel surface, and
this clinical appearance is nearly always speciﬁc for TSC (Fig
5). Smaller collagenomas on the trunk exhibit the same
histologic changes as shagreen patches but are less speciﬁc
for TSC because theymay also occur as an isolated ﬁnding or
in other genetic syndromes including MEN1,26 BHD,30 and
Cowden syndrome.31 Shagreen patches are observed in
about 50% of individuals with TSC and typically have their
onset in the ﬁrst decade of life.15,16,18,21
“Confetti” skin lesions
Confetti skin lesions are numerous 1- to 3-mm hypo-
pigmented macules scattered over regions of the body such
as the arms and legs.31 Their frequency varies widely in
different studies, from 3% in children to about 58% over-
all.15,24 Despite their relatively low frequency, confetti le-
sions may still be useful for diagnosis and they were
retained as a minor feature. Their utility in adults is limited
by the fact that many adults in the general population
develop similar-appearing lesions as a consequence of
chronic sun exposure. In such cases, the diagnosis of
confetti lesions may be supported by a history of onset in
FIGURE 6.
Dental pits indicated by arrows.
FIGURE 8.
Retinal hamartoma indicated by arrow.
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body region over another.
Dental enamel pits
Dental enamel pits, previously included as a minor
feature listed as “multiple, randomly distributed pits in
dental enamel” were again included as a minor feature (Fig
6). The designation was simpliﬁed to dental enamel pits
(3) for the entire dentition. Dental pits are much more
common in TSC patients than the general population, with
Mlynarczyk reporting 100% of adult TSC patients (n¼ 50) as
having pitting compared with 7% of 250 adult control sub-
jects.32 Because they are relatively common in the popula-
tion, they are listed as a minor feature.
Intraoral ﬁbromas
Gingivalﬁbromas have long been associatedwith TSC and
were listed as a minor feature in the 1998 consensus docu-
ment (Fig 7). They occur in about 20-50% of individuals with
TSC, with greater frequency in adults than children.15,21,33,34FIGURE 7.
Intraoral ﬁbromas (gingival and labial indicated by arrows).Fibromas in TSCmay also be observed on the buccal or labial
mucosaandeven the tongue,34 so this criterionwasmodiﬁed
to include ﬁbromas at other intraoral sites. A stipulationwas
added for the presence of two or more intraoral ﬁbromas
because solitary oral ﬁbromas may occur in the general
population, particularly on the tongue or buccal mucosa
along the bite line from repeated trauma.35,36
Bone cysts
Bone cysts were included in the 1998 criteria as a minor
feature of TSC. Because of the lack of speciﬁcity for TSC and
because the feature is rarely identiﬁed in the absence of
additional TSC clinical features, a decision was made to
delete “bone cysts” from the clinical diagnostic criteria.
Ophthalmologic features
Multiple retinal hamartomas
The ﬁnding of more than one retinal hamartoma was
determined to be signiﬁcant and speciﬁc enough to retain
as a major feature (Fig 8). These lesions have similar his-
tologic features to the tubers located in the brains of TSC
patients. They are observed in 30-50% of TSC patients and it
is not unusual to have multiple lesions in the same pa-
tient.37,38 The prevalence of retinal hamartomas in non-TSC
populations is not known, but rare case reports have been
made and a recent series of 3573 healthy term newborns
identiﬁed only two cases of astrocytic hamartomas in that
population.39 Fortunately, these lesions in TSC usually do
not cause problems with vision and are a good marker for
the disease, particularly in young children who might not
yet have many other features.
Retinal achromic patch
The presence of a retinal achromic patch was determined
at the 1998 conference to constitute a minor feature (Fig 9).
The assembled experts at the 2012 conference concurred
with the previous recommendation. Retinal achromic
patches are basically areas of hypopigmentation on the
retina. These patches have been noted to occur in 39% of TSC
FIGURE 9.
Retinal achromic patch indicated by arrow.
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mated at 1 in 20,000.41Central nervous system features
Because medical problems relating to the brain result in
the greatest morbidity and mortality in TSC, three panels at
the 2012 Consensus Conference devoted their efforts to
central nervous systemerelated ﬁndings of TSC. The panels
were: (3) brain structure, tubers, and tumors; (4) epilepsy;
and (5) TSC-associated neuropsychiatric disorders. The
three panels were in agreement that there should be three
neurological ﬁndings categorized as major features and that
the minor feature of cerebral white matter radial migration
lines should be subsumed into one of the major features as
reviewed in the following sections. Thus, ﬁndings relating
to the central nervous were streamlined.FIGURE 10.
(A) Axial magnetic resonance imaging (MRI) (T2 ﬂuid-attenuated inversion re
migration lines indicated by white and black arrows, respectively). (B) Axial MR
two white arrows) and subependymal giant cell astrocytoma (right, black arro
epilepsy.Cortical dysplasias
Cortical dysplasias are congenital abnormalities caused,
at least in part, when a group of neurons fail to migrate to
the proper area of the brain during development. The
cortical tubers observed in w90% of TSC patients and the
pathologic ﬁnding for which the disorder is named, are a
type of focal cortical dysplasia. Cerebral white matter radial
migration lines arise from a similar pathologic process as
cortical tubers and other forms of cortical dysplasia and in
TSC it is not unusual to ﬁnd tubers and white matter
migrational abnormalities together (Fig 10A). Both types of
cortical dysplasia in TSC are commonly associated with
intractable epilepsy and learning difﬁculties in TSC. The
pathologic and clinical overlap between “cortical tuber” as a
major feature and “cerebral white matter radial migration
lines” as a minor feature in the 1998 diagnostic criteriawere
felt to no longer represent separate processes and are
replaced with a single major feature in the new classiﬁca-
tion “cortical dysplasia.” However, it is appreciated that a
single area of focal cortical dysplasia or even two can be
observed in an individual who does not have TSC; thus, in
the new diagnostic criteria, multiple areas of focal cortical
dysplasia count only as one major feature and additional
clinical features are necessary to establish a deﬁnite diag-
nosis of TSC.
Subependymal nodules and subependymal giant cell astrocytomas
Subependymal nodules (SEN) and subependymal giant
cell astrocytoma (SEGA) will continue to represent two
separatemajor features (Fig 10B). Both of these lesions were
also included in the 1998 Consensus Conference Criteria as
major features. Histologically, the two lesions are similar
and both are relatively speciﬁc toTSC although not exclusive
to the disorder. Subependymal nodules are benign growths
that develop along the wall of the ependymal lining of the
lateral and third ventricles. They are observed in 80% of TSC
patients and often prenatally detected or at birth.42 SEGAscovery) of the brain, demonstrating cortical dysplasia (tubers and radial
I (T1 þ contrast) of the brain, demonstrating subependymal nodules (left,
w). This patient also has undergone previous partial frontal lobectomy for
FIGURE 11.
Echocardiogram indicating cardiac rhabdomyomas (arrows).
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prenatally or at birth, although they aremuchmore likely to
arise during childhood or adolescence and it would be un-
usual for one to occur after the age of 20 years if not already
previously present.42 It is widely accepted that SEGAs
typically arise from SEN, especially near the foramen of
Monro. Although benign and typically slow-growing, they
can cause serious neurologic compromise including
obstructive hydrocephalus. Both SENs and SEGAs may
progressively calcify over time.42
Cardiovascular features
The cardiology panel recommended retaining “cardiac
rhabdomyoma” as a major feature and determined that
there is no need to specify one versus more than one.FIGURE 12.
Axial high-resolution chest computed tomography, demonstrating
lymphangioleiomyomatosis.Cardiac rhabdomyoma
Cardiac rhabdomyomas are benign tumors of the heart
that are rarely observed in non-TSCeaffected individuals
(Fig 11). These lesions usually do not cause serious medical
problems, but they are highly speciﬁc to TSC and often the
ﬁrst noted manifestation of disease, and therefore remain a
major feature. Tumors are most frequently located in the
ventricles, where they can compromise ventricular function
and on occasion interfere with valve function or result in
outﬂow obstruction.43 These tumors are frequently
observed in TSC-affected individuals during fetal life but
after birth, they often regress and in some individuals may
no longer be detectable by echocardiographic examina-
tion.44,45 They are associated with cardiac arrhythmias
including atrial and ventricular arrhythmia and the Wolff-
Parkinson-White syndrome.
The prenatal presence of a cardiac rhabdomyoma is
associated with a 75-80% risk of TSC, with multiple rhab-
domyomas conveying an even higher risk.46-48 Further, in
the era preceding genetic testing, there was a <0.1%
occurrence of cardiac rhabdomyoma in individuals not
affected with TSC. Because they are frequently observed in
fetal life, unlike other ﬁndings in TSC, they are important in
bringing the patient to medical attention early in life. At
that point, new interventions may be more likely to
improve prognosis.
Pulmonary features
The pulmonology panel recommended retaining the
ﬁnding of lymphangioleiomyomatosis (LAM) as a major
feature of the clinical criteria to diagnose TSC. The other
experts agreed with this recommendation.
Lymphangioleiomyomatosis
Histologically, LAM is associated with interstitial
expansion of the lung with benign-appearing smooth
muscle cells that inﬁltrate all lung structures.49,50 Patients
typically present with progressive dyspnea on exertion and
recurrent pneumothoraces in the third to fourth decade of
life. Cystic pulmonary parenchymal changes consistent with
LAM are observed in 30-40% of female TSC patients (Fig 12),
but recent studies suggest that lung involvement may in-
crease with age such that up to 80% of TSC females are
affected by age 40.51 Cystic changes consistent with LAM are
also observed in about 10-12% of males with TSC, but
symptomatic LAM in males is very rare.52,53 It is important
to note that lung is rarely biopsied in TSC patients with
pulmonary parenchymal changes, so it is possible that
processes other than LAM may result in cystic lung disease
in TSC patients. LAM is also diagnosed in individuals who do
not have TSC, and is referred to as sporadic LAM (S-LAM).49
In these patients, LAM is thought to occur through two
somatic mutations in the TSC2 gene, rather than through a
germ line mutation and a “second-hit” somatic mutation
that is typical for TSC.54 That about one third of S-LAM
patients have renal angiomyolipomas, another major
feature in the diagnostic criteria for TSC, led to the conclu-
sion by the 1998 consensus group that when both angio-
myolipoma and LAM were present, other TSC features must
be present for the diagnosis of TSC (status per current
Consensus Conference discussed in next section). The
FIGURE 13.
Axial abdominal computed tomography, illustrating multiple bilateral renal
angiomyolipomata. The darker areas are fat containing angiomyolipoma-
tous tissue.
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ciple that TSC diagnostic criteria must clearly differentiate
S-LAM from TSC-LAM, and suggested the following modi-
ﬁed language: “When angiomyolipomas and LAM are both
present in a patient with suspected TSC, together they
constitute only one major criterion.”
The diagnosis of LAM as deﬁned by the pulmonology
panel is: (1) pathologic examination consistent with LAM,
(2) characteristic as deﬁned by the European Respiratory
Society (ERS) criteria high-resolution chest computed to-
mography (HRCT) with profusion of cysts (>4) and no
confounding comorbid conditions or exposures in a patient
with at least one other major criteria for TSC (other than
angiomyolipoma), or two other minor criteria, OR (3)
characteristic or compatible (ERS criteria) HRCT in the
setting of no confounding comorbid conditions or expo-
sures, plus one of the following: abdominal or thoracic
lymphangioleiomyomas, chylous pleural effusion, or
chylous ascites.49
Other manifestations of tuberous sclerosis in the lung
include multifocal micronodular pneumocyte hyperplasia
(MMPH) and clear cell tumor of the lung. In MMPH, mul-
tiple pulmonary nodules composed of benign alveolar type
II cells are found scattered throughout the lung. These le-
sions stainwith cytokeratin and surfactant proteins A and B,
but not with HMB-45, alpha smooth muscle actin, or hor-
monal receptors.55 MMPH does not have known prognostic
or physiologic consequences, although there have been at
least two reports of respiratory failure associated with
MMPH.55,56 The precise prevalence of MMPH in patients
with TSC is not known, but may be as high as 40-58%.57,58
There is no gender restriction and MMPH may occur in
the presence or absence of LAM in patients with TSC.58
MMPH can be confused with atypical adenomatoushyperplasia, which is premalignant lesion that is not clearly
associated with TSC. Clear cell tumor of the lung (CCSTL) is a
rare and typically benign mesenchymal tumor composed of
histologically and immunohistochemically distinctive peri-
vascular epithelioid cells. Together LAM, angiomyolipoma,
and CCSTL constitute the major members of the PEComa
family of lung tumors.59 The members of the pulmonary
subcommittee did not feel that the speciﬁcity of MMPH and
CCSTL for TSC have been established with sufﬁcient clarity
to suggest their inclusion as diagnostic criteria.Renal features
The nephrology panel attending the Consensus Confer-
ence agreed with deleting the designation of “renal” in the
major feature “renal angiomyolipomas” to now use
“angiomyolipomas 2” in the clinical diagnostic criteria.
Angiomyolipomas have been identiﬁed in TSC patients in
organs other than the kidney including the liver.60 As a
result, “angiomyolipomas (2)” was added to the major
features. The nephrology panel recommended not using the
abbreviation “AMLs” for angiomyolipomas. Although this
abbreviation has been commonly used among individuals
familiar with TSC, in most medical contexts it is more
familiarly associated with acute myelocytic leukemia and
thus introduces confusion across specialties. The
nephrology panel also recommended retaining “multiple
renal cysts” as a minor feature. This recommendation was
accepted by the other panelists. Additionally, it was agreed
that an individual who has LAM and renal angiomyolipomas
but no other features of TSC does not meet criteria for a
deﬁnite diagnosis because of the previously reviewed in-
formation regarding S-LAM.
Renal manifestations in TSC are an important source of
morbidity and mortality. In the only publication assessing
mortality associated with TSC,61 renal problems in TSC were
the second leading cause of premature death after severe
intellectual disability. With advances in medical care, death
in TSC from renal disease is much less likely; however, it
continues to represent a signiﬁcant medical burden to TSC
patients.
Angiomyolipomas
Angiomyolipomas are benign tumors composed of
vascular, smooth muscle, and adipose tissue (Fig 13).62
These benign tumors are observed most commonly in TSC
patients in the kidney but can occur in other organs. To be
inclusive of angiomyolipomas in other organs, it was
decided to delete “renal” and simply use the term “angio-
myolipomas (N  2)” as a major recognized feature.
Angiomyolipomas are a feature relatively speciﬁc to TSC.
Fat-containing angiomyolipomas were observed in 80% of
TSC patients, and fat-poor lesions are also common in pa-
tients with TSC, but occur in less than 0.1% of the general
population.63 Angiomyolipomas in the kidney can cause
serious issues with bleeding because of its vascular nature
and can lead to need for dialysis and even renal
transplantation.64
Multiple renal cysts
Multiple renal cysts are not commonly observed in the
general population,65 but can be seen in TSC patients who
H. Northrup, D.A. Krueger / Pediatric Neurology 49 (2013) 243e254 251have a TSC1 or TSC2mutation or as part of a contiguous gene
deletion syndrome involving the TSC2 and PKD1 genes.62
The TSC2 and PKD1 genes are immediately adjacent and
transcribed in opposite directions on chromosome 16p13.3.
Deletions involving both genes have been described in a
small subset of TSC patients who have the TSC phenotype as
well as an aggressive PKD phenotype.66 Presence of multi-
ple simple renal cysts in older individuals in the general
population is well-described, thus the decisionwas made to
specify multiple renal cysts and relegate this feature to the
minor status. In cross-sectional studies the number of cysts
in healthy people vary with age and standards have been
derived to help diagnose speciﬁc cystic disease states.
Endocrine features
LimitedﬁndingsofTSChavebeenreported intheendocrine
system.Variouskinds ofhamartomadooccur in theendocrine
system.67 According to early reports, adrenal angiomyolipoma
can be present in a quarter of TSC patients, but rarely, if ever,
causes hemorrhage.68-70 Thyroid papillary adenoma have
been reported in TSC patients,71,72 but did not cause thyroid
dysfunction. There are rare case reports of other angiomyoli-
poma or ﬁbroadenoma in the pituitary gland, pancreas, or
gonads.67 These tumors are considered as representingminor
features under the designation “nonrenal hamartomas.” The
recommendation was made by the endocrinology panel to
retain nonrenal hamartomas as a minor feature to include
these ﬁndings in the endocrine system of TSC-affected in-
dividuals. It was speculated that neuroendocrine tumors
mightbe slightlymoreprevalent inTSCpatients.67,73However,
neuroendocrine tumors are not hamartomas and are not
considered part of the diagnostic criteria.
Gastrointestinal features
Similarly, gastrointestinal manifestations in TSC patients
are fairly rare. Liver angiomyolipomas are reported in 10-
25% of TSC patients,74 and these lesions are included in the
major features group under the heading “Angiomyolipo-
mas” (discussed previously). Hamartomatous rectal polyps
were included as a minor feature in the 1998 Diagnostic
Criteria. It was decided because of the lack of speciﬁcity for
TSC and because they are another type of “nonrenal
hamartoma” that the speciﬁc designation of “hamartoma-
tous rectal polyps” would be deleted from the minor
criteria.
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